InVivo Therapeutics Announces FDA Approval to Expedite Enrollment for Ongoing Pilot Trial
Business Wire - Tue Dec 16, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced approval by the U.S. Food and Drug Administration (FDA) for an expedited enrollment plan for the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. Under the new plan, barring significant safety issues, InVivo will submit two months of safety data to the FDA for the first subject enrolled in October, and will then open enrollment for the second subject in mid-January (about three months after the first subject was enrolled). Upon enrollment of the second subject, InVivo will submit to the FDA one month of safety data for that subject together with the previous subject's data; concurrent enrollment for the remaining three subjects will then begin (about two months after the second subject is enrolled). There will be no additional mandatory holds between enrollment of the final three subjects. This differs from the previous plan, which required a mandatory three-month hold between sequential enrollment of each of the five subjects.
InVivo Therapeutics Announces University of Pittsburgh Medical Center Presbyterian as New Clinical Trial Site for Neuro-Spinal Scaffold
Business Wire - Tue Nov 25, 7:01AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the University of Pittsburgh Medical Center (UPMC) Presbyterian in Pittsburgh, PA as a clinical site in the company's ongoing IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). UPMC is the largest non-governmental employer in Pennsylvania (with more than 62,000 employees) and operates more than 20 academic, community, and specialty hospitals and 400 outpatient sites. David Okonkwo, MD, PhD, is the Director of Neurotrauma and Director of Scoliosis and Spinal Deformity at UPMC Presbyterian and Associate Professor of Neurological Surgery and Clinical Director of the Brain Trauma Research Center at the University of Pittsburgh. Dr. Okonkwo will be the study's Principal Investigator at that site.
Can InVivo Therapeutics Holdings (NVIV) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 7:35AM CST
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on NVIV’s earnings for the coming quarter and year.
InVivo Therapeutics Announces Oregon Health & Science University as Fifth Clinical Trial Site for Neuro-Spinal Scaffold
Business Wire - Fri Nov 21, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Oregon Health & Science University (OHSU) in Portland, OR is the fifth clinical site in the company's ongoing IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). OHSU is a nationally prominent research university and Oregon's only public academic health center, seeing nearly one million patients every year. Ahmed Raslan, MD, an Assistant Professor of Neurological Surgery at OHSU, will be the study's Principal Investigator at that site.
Medical Device Makers Are Cheering After Latest Victory from GOP
ACCESSWIRE - Fri Nov 14, 10:15AM CST
CORAL GABLES, FL / ACCESSWIRE / November 14, 2014 / For Democrats, the "wounds" are still fresh. A new GOP senate now rules "the Hill" and amidst the fog of uncertainty for some key decisions has arisen one clear standout, which is Obamacare (The Affordable Care Act); more specifically the tax it placed on medical devices. See, the Affordable Care Act imposes a 2.3% excise tax on the sale of medical devices, which in most cases is one of the highest effective tax rates of nearly any industry in the world...and go figure, the US is the only country to impose such a tax on medical devices. In the end, it seems like it has come down to jobs or specifically the ones that have been lost because of the tax. In fact according to the Advanced Medical Technology Association, the Medical Device Tax has cost the industry about 14,000 jobs and prevented the creation of nearly 20,000 more. Now the rise for repeal has begun to echo on Capitol Hill from both parties and in turn, the market has reacted.
InVivo Therapeutics
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:56PM CST
STEM: 0.90 (+0.03), AST: 3.22 (+0.01), CUR: 2.70 (+0.07)
InVivo Therapeutics names Ann Merrifield to board
M2 - Wed Nov 12, 7:13AM CST
Biotechnology company InVivo Therapeutics Holdings (Other OTC:NVIV) disclosed on Tuesday the addition of Ann Merrifield to its board of directors.
Barrow Neurosurgeons Implant the World's First Scaffold into a Patient's Spinal Cord
PR Newswire - Tue Nov 11, 1:00PM CST
Performed last month, the surgery involves inserting a bioresorbable scaffolding implant to act as a bridge across the gap of the injured section of the cord in an attempt to help the spinal cord heal. This first case is part of a pilot study to measure the clinical safety of the implanted device developed by InVivo Therapeutics Holdings Corp. If proven successful, surgeons believe the new technique could become a standard protocol in the treatment of acute spinal cord injury.
InVivo Therapeutics Announces Appointment of Ann Merrifield to Its Board of Directors
Business Wire - Tue Nov 11, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Ann Merrifield to its Board of Directors. Ms. Merrifield most recently was President and Chief Executive Officer at PathoGenetix, a genomics company that developed and commercialized an automated system for rapid bacterial identification from complex samples.
InVivo Therapeutics beats by $0.01
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 5:13PM CST
InVivo Therapeutics Reports 2014 Third Quarter Financial Results and Business Update
Business Wire - Wed Nov 05, 3:30PM CST
InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended September 30, 2014.
InVivo Therapeutics Receives FDA Approval to Broaden Inclusion Criteria and Add 14 Additional Sites (20 Total) for Ongoing Pilot Trial
Business Wire - Wed Oct 29, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the US Food and Drug Administration (FDA) has approved various changes to the protocol for the company's ongoing IDE pilot trial for acute spinal cord injury (SCI), including expanding the number of allowable clinical sites to 20 (previously six) and broadening the eligibility criteria. With this approval, the upper end of the age range has been increased from 55 to 65, the spinal cord injury level has been expanded from T3-T11 to T3-T12/L1, the enrollment window has been extended from 10 to 21 days post injury, and the Body Mass Index upper limit has been increased from 35 to 39.
InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc.
PR Newswire - Wed Oct 22, 6:30AM CDT
InVivo Therapeutics Holdings Corp. (OTCQB: NVIV) based in Cambridge, MA is revolutionizing spinal cord injury (SCI) treatment with their novel Neuro-Spinal Scaffold. This technique has been shown to outperform in tissue regrowth in the spinal cord area when cells are coupled with the scaffold. Made from an FDA approved polymer, the scaffold ultimately breaks down to water and carbon dioxide; making it harmless to the human body. NVIV has recently attracted significant investor attention with the announcement of the enrollment of the first subject in the pilot spinal cord injury trial and the approval of a fourth clinical site for the pilot study. The Company observed a 42% surge in their share price on a volume of 3,759,766 shares against an average daily volume of 355,474 shares on Oct 15, 2014 and 21.35% increase on 1,046,749 shares on Oct 20, 2014 pushing the share price above the 50-day SMA of $0.61. NVIV is still trading well below the 200-day SMA of $1.39; however with IRB approval for two additional clinical sights set to be announced in the coming weeks, a strong 2014 finish is expected for NVIV.
InVivo Therapeutics Announces Barnes-Jewish Hospital at Washington University as New Clinical Trial Site for Neuro-Spinal Scaffold
Business Wire - Mon Oct 20, 7:01AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Barnes-Jewish Hospital at Washington University Medical Center in St. Louis, MO, is the fourth clinical site in the company's on-going IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). Barnes-Jewish Hospital is the largest regional trauma center in St. Louis and is one of the largest clinical spine care practices for the United States. Paul Santiago, MD, an Associate Professor of Neurological Surgery and Orthopedic Surgery at the Washington University School of Medicine in St. Louis, will be the study's Principal Investigator at the Barnes-Jewish Hospital.
InVivo, Neuralstem Treat Spinal Cord Injury Patients
Jason Napodano, CFA - at Seeking Alpha - Thu Oct 16, 12:53PM CDT
CUR: 2.70 (+0.07)
InVivo Therapeutics enrolls first acute spinal cord injury patient at St Joseph's Hospital and Medical Center trial
M2 - Thu Oct 16, 8:47AM CDT
Biotechnology company InVivo Therapeutics Holdings (other OTC:NVIV) disclosed on Wednesday the admission of the first subject in the pilot study of its Neuro-Spinal Scaffold for the treatment of complete traumatic spinal cord injury (SCI) in Phoenix, AZ.
InVivo Therapeutics Announces First Subject Enrolled in Pilot Spinal Cord Injury Trial
Business Wire - Wed Oct 15, 7:01AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the first subject has been enrolled in the pilot study of its Neuro-Spinal Scaffold for the treatment of complete traumatic spinal cord injury (SCI) at the Barrow Neurological Institute at St. Joseph's Hospital and Medical Center in Phoenix, AZ. The objective of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold as well as to gather preliminary evidence of effectiveness.
InVivo Therapeutics to Exhibit at 2014 Congress of Neurological Surgeons Annual Meeting
Business Wire - Mon Oct 06, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the Company will be exhibiting at the 2014 Congress of Neurological Surgeons (CNS) Annual Meeting, to be held in Boston, MA October 18-22. The exhibit, InVivo's first at a major medical conference, will focus on strengthening and expanding the Company's neurosurgical network and increasing awareness about its ongoing clinical pilot study of the Neuro-Spinal Scaffold to treat acute spinal cord injury. InVivo will also host a social event in conjunction with the Congress, which is estimated to draw more than 3,000 attendees this year.
Deadline Monday: Levi & Korsinsky, LLP Reminds Investors of Class Action Against InVivo Therapeutics Holdings Corp. and Its Board of Directors and a Lead Plaintiff Deadline of October 6, 2014
Business Wire - Fri Oct 03, 11:06AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company"
UPCOMING DEADLINE ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in InVivo Therapeutics Holdings Corp. to Contact the Firm Before the October 6, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- NVIV
GlobeNewswire - Thu Oct 02, 5:00AM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court of Massachusetts on behalf of purchasers of InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company"